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Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an important healthcare-associated patho-
gen. We evaluated the impact of CRKP strain type and treatment on outcomes of patients with CRKP bacteriuria.
Patients and methods: Physician-diagnosed CRKP urinary tract infection (UTI)—defined as those patients who
received directed treatment for CRKP bacteriuria—was studied in the multicentre, prospective Consortium on
Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle) cohort. Strain typing by repetitive extragenic
palindromic PCR (rep-PCR) was performed. Outcomes were classified as failure, indeterminate or success.
Univariate and multivariate ordinal analyses to evaluate the associations between outcome, treatment and
strain type were followed by binomial analyses.
Results: One-hundred-and-fifty-seven patients with physician-diagnosed CRKP UTI were included. After adjust-
ment for CDC/National Healthcare Safety Network (NHSN)-defined UTI, critical illness and receipt of more than
one active antibiotic, patients treated with aminoglycosides were less likely to fail therapy [adjusted OR (aOR) for
failure 0.34, 95% CI 0.15–0.73, P¼0.0049]. In contrast, patients treated with tigecycline were more likely to fail
therapy (aOR for failure 2.29, 95% CI 1.03–5.13, P¼0.0425). Strain type data were analysed for 55 patients. The
predominant clades were ST258A (n¼18, 33%) and ST258B (n¼26, 47%). After adjustment for CDC/NHSN-
defined UTI and use of tigecycline and aminoglycosides, infection with strain type ST258A was associated
with clinical outcome in ordinal analysis (P¼0.0343). In multivariate binomial models, strain type ST258A was
associated with clinical failure (aOR for failure 5.82, 95% CI 1.47–28.50, P¼0.0113).
Conclusions: In this nested cohort study of physician-diagnosed CRKP UTI, both choice of treatment and CRKP
strain type appeared to impact on clinical outcomes.
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Introduction
Infections with carbapenem-resistant Klebsiella pneumoniae
(CRKP) represent a growing threat to patients in the USA and world-
wide.1 The treatment of these infections is problematic, as few
therapeutic options are available.2 Antibiotics that may retain
in vitro activity against CRKP include polymyxins such as colistin,
tigecycline and aminoglycosides. Novel therapies that promise
to be effective against CRKP, such as ceftazidime/avibactam,
plazomicin and BAL30072, are still far from the armamentarium
of the physician.
Most CRKP in the USA produce carbapenemases of the K. pneumo-
niae carbapenemase (KPC) family. In addition, metallo-b-lactamases
such as New Delhi metallo-b-lactamase (NDM-1) are prevalent
causes of carbapenem resistance in Enterobacteriaceae in other
parts of the world, and are beginning to be reported in the USA as
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well.3,4 The most common endemic strain of CRKP is ST258 by MLST,
which can be further subdivided into clinically and microbiologically
distinct clades by the use of high-resolution restriction mapping,
repetitive extragenic palindromic PCR (rep-PCR) and whole-genome
sequencing.3,5 In most patients who have CRKP isolated during
their hospitalization, CRKP is found in urine cultures.3 About a third
of patients with CRKP bacteriuria meet CDC/National Healthcare
Safety Network (NHSN) criteria for urinary tract infection (UTI).3,6
However, these criteria were primarily designed for surveillance pur-
poses, and many patients with CRKP bacteriuria who do not meet
these criteria are thought to have UTI by their providers and receive
directed treatment. To address this point, we describe the impact of
various treatment regimens on the outcomes of patients who were
treated with antibiotics directed against CRKP—colistin, tigecycline,
aminoglycosides, fosfomycin and trimethoprim/sulfamethoxa-
zole—for CRKP bacteriuria, while adjusting for the presence of UTI
as defined by CDC/NHSN. Our primary aims were to evaluate the




The multicentre, prospective Consortium on Resistance against
Carbapenems in Klebsiella pneumoniae (CRaCKle) study was described
previously.3 The current study represents a nested cohort within
CRaCKle. All hospitalized patients who had a urine culture that grew
CRKP and who received active treatment within 7 days of their first positive
urine culture during their hospitalization were included if their index hos-
pitalization began and ended in the study period, 24 December 2011 to
1 October 2013. Patients were included once at the time of their first
episode of treated CRKP bacteriuria. The institutional review boards of all
health systems involved approved the study.
Definitions
The index hospitalization was designated as the first hospital stay within
the study period during which CRKP was isolated from the urine followed
by active treatment within 7 days. Active treatment was defined as receipt
of an aminoglycoside, colistin, tigecycline, trimethoprim/sulfamethoxa-
zole or fosfomycin, unless in vitro resistance was documented to that anti-
microbial in the patient’s isolate, following CLSI (aminoglycosides,
trimethoprim/sulfamethoxazole and fosfomycin) and EUCAST (colistin
and tigecycline) guidelines. The base of the regimen was assigned as fol-
lows: any regimen that contained an aminoglycoside was deemed
aminoglycoside-based; any regimen that contained colistin, but not an
aminoglycoside, was deemed colistin-based; and any regimen that con-
tained tigecycline, but not colistin or an aminoglycoside, was deemed
tigecycline-based. All other regimens were classified as ‘other’.
Criteria as outlined by CDC/NHSN were used to define UTI and asymptom-
atic bacteraemic UTI (ABUTI); these two categories were grouped together as
CDC/NHSN-defined UTI for analysis purposes.6 Non-physiological urinary
drainage was defined as the presence of an indwelling urinary catheter, per-
manent urinary diversion or intermittent urinary catheterization. All other
patients were considered to have physiological urinary drainage.
Critical illness was defined as a Pitt bacteraemia score ≥4 points on the
day of the index urine culture.7 Treatment failure was defined as patients
who had recurrent CRKP isolated from the urine at least 7 days after their
index culture. In addition, those who did not survive their index hospital-
ization (death or discharge to hospice) were considered treatment failures.
Treatment success was defined as patients who had a negative urine cul-
ture documented after their index culture and who did not meet any of the
criteria for treatment failure. Treatment outcome was deemed indeter-
minate in those patients who did not meet criteria for success or failure.
Microbiology
CRKP is defined as K. pneumoniae isolates with non-susceptibility to the
following carbapenems as per CLSI guidelines: meropenem, imipenem
or ertapenem.8 Bacterial identification and routine antimicrobial suscepti-
bility testing was performed with MicroScan (Siemens Healthcare
Diagnostics) or Vitek 2 (bioMérieux), supplemented by a GN4F Sensititre
tray (Thermo Fisher) to confirm carbapenem results and to test tigecycline
susceptibility.
Detection of carbapenemases in CRKP and strain typing
Detection of carbapenemase genes and rep-PCR strain typing was per-
formed as previously described.3 Briefly, PCR amplification of blaKPC,
blaNDM, blaVIM, blaIMP and blaOXA-48 genes was conducted using established
primers and methods; amplicons were sequenced at a commercial
sequencing facility (MCLAB, San Francisco, CA, USA) and analysed.9,10
rep-PCR was performed using the DiversiLab strain typing system
(Bacterial BarCodes, bioMérieux, Athens, GA, USA). Isolates with ≥95%
similarity were considered to be of the same rep-PCR type. MLST was per-
formed on CRKP isolates from the predominant rep-PCR types, as previ-
ously described.11 Sequences of seven housekeeping genes (rpoB, gapA,
mdh, pgi, phoE, infB and tonB) were compared with the MLST database
(http://www.pasteur.fr/recherche/genopole/PF8/mlst).
Analysis
The primary outcome was analysed as an ordinal variable in the following
order: failure, indeterminate, success. Ordinal logistic regression was used
to estimate associations between outcomes and microbiological and clin-
ical variables. For all models, ordinal lack-of-fit testing was performed to
rule out a poorly fitted model. In addition, for the purpose of sensitivity
analysis, as well as to estimate effect sizes, all associations were evaluated
in binomial logistic models either combining indeterminates with success
(i.e. comparing patients with failure versus all others) or with failure (i.e.
comparing patients with success versus all others). Barnard’s exact test
was used to compare proportions. The Brown–Mood median test was
used to compare medians. All analyses were performed using JMP soft-
ware (SAS Inc., Cary, NC, USA).
Results
Patients
During the 21 month study period, 157 unique patients with
physician-diagnosed CRKP UTI were included in the study
(Figure 1). Their clinical characteristics are outlined in Table 1.
Median follow-up time from date of discharge of the index
hospitalization to the end of the study period was 306 days (IQR
193–487 days). Antimicrobial susceptibility testing was per-
formed as clinically indicated (Figure 2). Colistin and amikacin
demonstrated the most reliable in vitro activity, with susceptibility
rates of 91% and 83% in tested isolates, respectively. Only five iso-
lates were tested against fosfomycin; four of these were resistant.
UTI as defined by NHSN
Within this cohort of 157 patients with physician-diagnosed CRKP
UTI, 53 (34%) met CDC/NHSN criteria for UTI. Of these 53 patients,
10 (19%) had CRKP bacteraemia. In addition, 2 (4%) and 2 (4%)
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patients had CRKP isolated from wounds and respiratory tract,
respectively. Of the 104 patients who did not meet criteria for
infection, 14 (13%) had CRKP isolated from non-urinary sources,
8 (8%) from wounds and 3 (3%) from respiratory sources, and 3
(3%) had CRKP bacteraemia .24 h after their urine culture.
Outcomes
In 23 (15%) of 157 patients with physician-diagnosed UTI, treat-
ment success was documented, whereas 54 patients (34%) were
deemed treatment failures. The remaining 80 patients (51%) had
an indeterminate outcome. Of the 54 patients with treatment fail-
ure, 16 (30%) died and 1 (2%) was discharged to a hospice. The
remaining 37 (69%) patients had recurrent CRKP bacteriuria. In uni-
variate ordinal regression, CDC/NHSN-defined UTI, location at the
time of culture and critical illness were associated with outcome.
In a multivariable ordinal model including these variables and urin-
ary drainage, only the association with CDC/NHSN-defined UTI
remained significant (P¼0.0289). To determine the direction and
magnitude of these associations, we used multivariable binomial
models to compare patients with failure versus all others and
patients with success versus all others. In the multivariable bino-
mial model comparing patients with failure versus all others, critical
illness was associated with failure [adjusted OR (aOR) for failure
2.66, 95% CI 1.09–6.53, P¼0.0313]. None of the other variables
was associated with failure. In comparing success versus all
others, both CDC/NHSN-defined UTI (aOR for success 2.93, 95%
CI 1.13–7.85, P¼0.0273) and critical illness (aOR for success
3.62, 95% CI 1.08–11.98, P¼0.0376) were associated with
success. None of the other variables was associated with success.
Treatment
The majority of patients (110/157, 70%) received only one active
agent (Table 2). In patients who received a single active agent,
aminoglycosides (gentamicin or amikacin) or tigecycline were
260 patients with at least
one episode of CRKP bacteriuria
157 patients with CRKP bacteriuria
who received anti-CRKP treatment
(UTI n = 53)
In vitro active
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Figure 1. Flow diagram showing the treatment of patients in various outcome categories. UTI was as defined in CDC/NHSN criteria. SXT, trimethoprim/
sulfamethoxazole.
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most commonly used. Forty-seven (30%) patients received more
than one active agent, in a variety of combinations (Table 2).
Presence of CDC/NHSN-defined UTI was not associated with the
use of any specific antimicrobial. CDC/NHSN-defined UTI was
also not associated with receipt of more than one active agent;
16/53 (30%) patients with CDC/NHSN-defined UTI received more
than one agent compared with 31/104 (30%) patients without
CDC/NHSN-defined UTI (not significant). The administration of
fosfomycin was associated with absence of critical illness; none
of the 39 patients with critical illness received fosfomycin, com-
pared with 19/118 (16%) patients without critical illness
(P¼0.004). Critical illness was not associated with receipt of
more than one drug or any other treatment choice.
The association between the use of any single drug and out-
comes was evaluated in a multivariable ordinal logistic model
that included the drug in question, critical illness, the presence
of CDC/NHSN-defined UTI and the use of more than one active
antibiotic. In these models, use of aminoglycosides and tigecycline
Table 1. Clinical characteristics and outcomes
All Success Indeterminate Failure Pa Pb
n 157 23 80 54
Female 93 (59) 11 (48) 55 (69) 27 (50) 0.4260
Age (years), median (IQR) 72 (61–82) 73 (58–84) 74 (63–82) 71 (59–81) 0.4231
Race/ethnicity 0.9433
white 88 (56) 14 (61) 44 (55) 30 (56)
black 63 (40) 8 (35) 33 (41) 22 (41)
Hispanic 4 (3) 1 (4) 2 (3) 1 (2)
other 2 (1) 0 1 (1) 1 (2)
Charlson comorbidity index, median (IQR) 3 (2–5) 2 (1–4) 4 (2–5) 3.5 (2–6) 0.1653
Renal failure upon admissionc 34 (22) 3 (13) 18 (23) 13 (24) 0.3771
UTId 53 (34) 13 (57) 26 (33) 14 (26) 0.0210 0.0289
Urinary drainage 0.0783 0.3898
physiological 48 (30) 8 (35) 26 (33) 14 (26)
Foley catheter 82 (52) 9 (39) 39 (49) 34 (63)
other 27 (17) 8 (35) 15 (19) 6 (11)
Location at time of culture 0.0159 0.1974
ward 62 (39) 10 (43) 33 (41) 19 (35)
emergency department 61 (39) 10 (43) 35 (44) 16 (30)
ICU 34 (22) 3 (13) 12 (15) 19 (34)
LOS (days), median (IQR) 11 (7–17) 13 (10–17) 10 (6–16) 9 (6–21) 0.1393
Critical illnesse 39 (25) 8 (35) 9 (11) 22 (41) 0.0295 0.3792
Origin 0.4438
skilled nursing facility 86 (55) 13 (57) 47 (59) 26 (48)
home 44 (28) 4 (17) 22 (28) 18 (33)
hospital transfer 17 (11) 3 (13) 7 (9) 7 (13)
long-term acute care 10 (6) 3 (13) 4 (5) 3 (6)
Disposition —f
skilled nursing facility 78 (50) 12 (52) 45 (56) 21 (39)
home 33 (21) 5 (22) 20 (25) 8 (15)
long-term acute care 29 (18) 6 (26) 15 (19) 8 (15)
death 16 (10) — — 16 (30)
hospice 1 (1) — — 1 (2)
LOS, length of stay.
All data are expressed as n (%) unless otherwise indicated.
aP value indicating the univariate relationship between the variable of interest and the ordinal outcome (success, indeterminate, failure).
bMultivariable model including UTI, location, critical illness and urinary drainage.
cRenal failure defined as creatinine .2 mg/dL upon admission.
dUTI as defined by CDC/NHSN.
eCritical illness defined as Pitt bacteraemia score ≥4.
fNot analysed as disposition was part of the outcome definition.
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was associated with outcomes. Multivariable binomial models indi-
cated that patients treated with aminoglycosides were less likely to
fail therapy (aOR for failure 0.34, 95% CI 0.15–0.73, P¼0.0049),
whereas patients treated with tigecycline were more likely to fail
therapy (aOR for failure 2.29, 95% CI 1.03–5.13, P¼0.0425).
Neither the use of aminoglycosides (aOR for success 2.04, 95%
CI 0.80–5.45, P¼0.1362) nor the use of tigecycline (aOR for suc-
cess 0.59, 95% CI 0.19–1.65, P¼0.3165) was associated with
treatment success. To determine whether these associations
were influenced by the use of a composite definition for treatment
failure, we repeated the models after excluding the 17 patients
who did not survive their index hospitalization. The associations
between treatment choice and treatment failure remained signifi-
cant after excluding these patients (data not shown).
We then evaluated the associations between regimen base
and outcomes. In multivariable ordinal regression adjusting for
critical illness, CDC/NHSN-defined UTI and the use of more than
one active antibiotic, regimen base was associated with outcome
(P¼0.0083). Further evaluation of this effect with binomial ana-
lyses showed an association with failure (P¼0.0065), but not
with success (P¼0.4330). Using the aminoglycoside-based regi-
men group as the reference group, the aORs for failure were
1.92 (95% CI 0.63–5.76) for colistin-based regimens, 5.19 (95%
CI 2.03–14.13) for tigecycline-based regimens and 1.71 (95% CI
0.46–5.78) for other regimens.
A non-significant trend was seen towards association between
outcome and receipt of more than one active antibiotic in multi-
variable ordinal regression (P¼0.0575). Patients who received
more than one in vitro active agent were more likely to experience
failure (aOR for failure 2.53, 95% CI 1.21–5.37, P¼0.0141).
CRKP strains
The isolates of 55 patients were available for strain typing
(Table 3). Significant differences were not seen between patients
with available index isolates versus those whose isolates were
unavailable in demographics, treatment choices or outcomes
(data not shown). The predominant strain types were rep-PCR A
(n¼18, 33%) and B (n¼26, 47%), both part of the ST258 strain
complex.3 The remaining 11 patients had a variety of other strain
types identified by rep-PCR. The majority of isolates expressed
KPC; 24 (44%) carried blaKPC-2 and 29 (53%) carried blaKPC-3.
One isolate carried blaNDM-1 and one was negative for all carbape-
nemases tested.
None of the clinical variables was significantly associated with
ST258A, except for fosfomycin use, which was more common in
patients with ST258A (P¼0.0317). On univariate ordinal regres-
sion, strain type was not associated with outcome. We then con-
structed a multivariable ordinal regression model (Table 4) that
included strain type and the variables previously identified as
related to outcome (CDC/NHSN-defined UTI, tigecycline use and
aminoglycoside use). In this model, ST258A was associated with
outcome (P¼0.0343). In binomial models, ST258A was asso-
ciated with failure (aOR for failure 5.82, 95% CI 1.47– 28.50,
P¼0.0113), but not associated with success (aOR for success
0.73, 95% CI 0.12– 3.74, P¼0.7120). We also constructed a
model that included the base of the regimen used (Table 5). In
this model a trend towards association was seen for ST258A
and outcome (P¼0.0598). In the corresponding binomial models,
ST258A was again associated with failure (aOR for failure 5.07,
95% CI 1.32–23.59, P¼0.0176), but not associated with success
(aOR for success 0.89, 95% CI 0.14–4.62, P¼0.8935). To deter-
mine whether the increased failure rates of patients infected
with ST258A were related to the increased use of fosfomycin,
we repeated these models after exclusion of patients treated
with fosfomycin. The association between strain type and treat-
ment failure remained significant after excluding these patients
(data not shown). Furthermore, we evaluated whether these
results were influenced by the use of a composite outcome by
repeating the analyses excluding those patients who did not sur-
vive their index hospitalization (n¼7). Excluding these patients
also did not alter the association between strain type and treat-
ment failure (data not shown).
Discussion
This study shows that the outcomes of CRKP UTI are influenced by
both the choice of antimicrobial treatment and the CRKP strain
type. In this large prospective multicentre cohort, patients who
were treated with aminoglycosides enjoyed better outcomes,
whereas patients treated with tigecycline experienced worse out-
comes. These associations remained significant after adjustment
for relevant clinical co-variables. In addition, we report here the
first evidence that patients infected with the CRKP strain ST258A
are more likely to have treatment failure. The ST258 strain com-
plex is the most common strain complex of CRKP globally, and
was recently shown to consist of at least two clinically and
molecularly distinct strain types.3,5,12,13 The current finding that
ST258A is associated with worse outcomes after treated CRKP
bacteriuria adds to this growing knowledge base, and emphasizes
the link between clinical and molecular findings. The molecular
mechanisms causing these observed clinical differences between
patients with different CRKP strains remain unclear. Different
strains may carry different virulence factors encoded in chromo-
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Figure 2. Antimicrobial susceptibility patterns. SXT, trimethoprim/
sulfamethoxazole.
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to be more virulent compared with other CRKP strains in a
Caenorhabditis elegans model, whereas blaKPC-2 was not itself
associated with virulence.14 Candidates for virulence factors
that may differ between various strains include changes in
types of capsular polysaccharides (variations in the cps locus) or
the mere overproduction of these polysaccharides, expression of
iron chelators, mutations in porins such as OmpK35 and OmpK36
and other changes.15 – 17
The treatment of CRKP infections is challenging and, while new
antibiotic options are on the horizon, unfortunately these will
require time before they become widely available. In the mean-
time, most data on the treatment of CRKP infections have been
reported from patients with CRKP bloodstream infections, and
only limited data exist for other CRKP infections.18 – 21 Qureshi
et al.22 recently reported their retrospective experience in a cohort
of 21 patients with UTI. Interestingly, use of doxycycline for these
infections was common at their centre and resulted in clinical cure
in all nine patients treated in this way. In our cohort, doxycycline
was not a common treatment choice and was not included
in analyses. We noted that treatment with aminoglycosides
appeared to be associated with better outcomes. This is consist-
ent with data from Satlin et al.,23 who reported superior urinary
clearance with aminoglycoside therapy. In another study that
described a retrospective cohort that included seven patients
Table 2. Treatment
All Success Indeterminate Failure Pa Pb
n 157 23 80 54
Any in vitro active drug in first 7 days
aminoglycoside 76 (48) 14 (61) 42 (53) 20 (37) 0.0292 0.0041
colistin 27 (17) 4 (17) 11 (14) 12 (22) 0.3469 0.6531
tigecycline 66 (42) 8 (35) 26 (33) 32 (59) 0.0047 0.0365
SXT 18 (11) 2 (9) 11 (14) 5 (9) 0.7801 0.9633
fosfomycin 19 (12) 2 (9) 8 (10) 9 (17) 0.2168 0.2790
Base of regimenc 0.0269 0.0083
aminoglycoside 76 (48) 14 (61) 42 (53) 20 (37)
colistin 23 (15) 3 (13) 10 (13) 10 (19)
tigecycline 36 (23) 3 (13) 14 (18) 19 (35)
other 22 (14) 3 (13) 14 (18) 5 (9)
Single in vitro active drug in first 7 daysd 110 (70) 16 (70) 63 (79) 31 (57) 0.0500
aminoglycoside 47 (30) 8 (35) 28 (35) 11 (20) 0.2990 0.1004
colistin 11 (7) 2 (9) 8 (10) 1 (2) 0.2079 0.3182
tigecycline 30 (19) 3 (13) 13 (16) 14 (26) 0.0148 0.0102
SXT 14 (9) 2 (9) 9 (11) 3 (6) 0.6664 0.9531
fosfomycin 8 (5) 1 (4) 5 (6) 2 (4) 0.9444 0.9888
.1 in vitro active drug in first 7 dayse 47 (30) 7 (30) 17 (21) 23 (43) 0.0500 0.0575
aminoglycoside+tigecycline 17 (11) 4 (17) 9 (11) 4 (7) —
aminoglycoside+ fosfomycin 7 (4) 1 (4) 3 (4) 3 (6) —
aminoglycoside+colistin 2 (1) 1 (4) 0 1 (2) —
aminoglycoside+colistin+tigecycline 2 (1) 0 1 (1) 1 (2) —
aminoglycoside+SXT 1 (1) 0 1 (1) 0 —
colistin+tigecycline 11 (7) 1 (4) 2 (3) 8 (15) —
colistin+ fosfomycin 1 (1) 0 0 1 (2) —
tigecycline+SXT 3 (2) 0 1 (1) 2 (4)
tigecycline+ fosfomycin 3 (2) 0 0 3 (6)
SXT, trimethoprim/sulfamethoxazole.
All data are expressed as n (%), unless otherwise indicated.
aP value indicating the univariate relationship between the variable of interest and the ordinal outcome (success, indeterminate, failure).
bAdjusted for the presence of UTI, critical illness and for receipt of more than one anti-CRKP drug (except for single drug variables and single drug versus
multiple drugs, which were adjusted for UTI only).
cBase of regimen was assigned as follows: any regimen that contained an aminoglycoside was deemed aminoglycoside-based; any regimen that
contained colistin, but not an aminoglycoside, was deemed colistin-based; and any regimen that contained tigecycline, but not colistin or an amino-
glycoside, was deemed tigecycline-based. All other regimens were classified as ‘other’.
dComparisons are made within the single drug group.
eThe group of patients who received more than one drug was compared with those who received a single drug. No analyses were performed on individual
combination regimens secondary to small numbers.
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Table 3. Strain types
All ST258A ST258B Other Pa
n 55 18 26 11
Female 27 (49) 11 (61) 12 (46) 4 (36) 0.1788
Age (years), median (IQR) 69 (59–80) 66 (51–73) 73 (61–83) 69 (60–85) 0.3801
Race/ethnicity 0.4595
white 35 (64) 11 (61) 16 (62) 8 (73)
black 17 (31) 5 (28) 9 (35) 3 (27)
Hispanic 2 (4) 1 (6) 1 (4) 0
other 1 (2) 1 (6) 0 0
Charlson comorbidity index, median (IQR) 3 (2–5) 3 (1–4) 4.5 (2–6) 3 (2–5) 0.1691
Renal failure upon admissionb 15 (27) 4 (22) 7 (27) 4 (2–5) 0.3984
UTIc 19 (35) 6 (33) 8 (31) 5 (45) 0.4801
Urinary drainage 0.6588
physiological 16 (29) 4 (22) 9 (35) 3 (27)
Foley catheter 32 (58) 12 (67) 15 (58) 5 (45)
other 7 (13) 2 (11) 2 (8) 3 (27)
Location at time of culture 0.7153
ward 26 (47) 9 (50) 10 (38) 7 (64)
emergency department 16 (29) 4 (22) 11 (42) 1 (9)
ICU 13 (24) 5 (28) 5 (19) 3 (27)
LOS (days), median (IQR) 12 (8–22) 18 (8–41) 12 (8–20) 11 (9–28) 0.2093
Critical illnessd 14 (25) 6 (33) 5 (19) 3 (27) 0.2253
Origin 0.2989
skilled nursing facility 21 (38) 7 (39) 12 (46) 2 (20)
home 20 (36) 8 (44) 8 (31) 4 (36)
hospital transfer 10 (18) 3 (17) 3 (12) 4 (36)
long-term acute care 4 (7) 0 3 (12) 1 (9)
Disposition 0.8829
skilled nursing facility 25 (45) 8 (44) 13 (50) 4 (36)
home 15 (27) 4 (22) 8 (31) 3 (27)
long-term acute care 8 (15) 3 (17) 2 (8) 3 (27)
death 7 (13) 3 (17) 3 (11) 1 (9)
Any in vitro active drug in first 7 days
aminoglycoside 26 (47) 7 (39) 12 (46) 7 (64) 0.2435
colistin 10 (18) 5 (28) 5 (19) 0 0.1788
tigecycline 21 (38) 5 (28) 11 (42) 5 (45) 0.1789
SXT 7 (13) 1 (6) 4 (15) 2 (18) 0.1789
fosfomycin 7 (13) 5 (28) 1 (4) 1 (9) 0.020
.1 in vitro active drug in first 7 days 15 (27) 5 (28) 6 (23) 4 (36) 0.5049
Outcome 0.1073
success 9 (16) 3 (17) 4 (15) 2 (18)
indeterminate 23 (42) 4 (22) 14 (54) 5 (45)
failure 23 (42) 11 (61) 8 (31) 4 (36)
LOS, length of stay; SXT, trimethoprim/sulfamethoxazole.
All data are expressed as n (%) unless otherwise indicated.
aComparing rep-PCR A versus all others.
bRenal failure defined as creatinine .2 mg/dL upon admission.
cUTI as defined by CDC/NHSN.
dCritical illness defined as Pitt bacteraemia score ≥4.
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who were treated with aminoglycosides, the same trend towards
increased efficacy of aminoglycosides was observed.24 In contrast,
tigecycline—which is primarily excreted through faeces and does
not achieve high urinary levels25—was associated with worse out-
comes in our cohort. In addition to this link to poor clinical out-
comes, we have recently reported that the use of tigecycline in
these patients is associated with the subsequent rapid develop-
ment of tigecycline resistance.26
Our study has several important limitations. First, the study of
UTIs is problematic as a universally accepted gold standard does
not exist. The distinction between colonization and infection is
quite difficult, especially in older patients with urinary catheters.
Therefore, we chose to study all patients in whom the treating
clinician deemed directed therapy was necessary, rather than
relying solely on criteria developed for the purpose of surveil-
lance. As expected, only a subset of patients who were treated
met criteria for UTI by CDC/NHSN guidelines. The disadvantage
of this approach is that patients with urinary CRKP colonization
may been included in whom antibiotic treatment was unlikely
to be of any clinical benefit. In all analyses, we have adjusted
for presence of UTI by CDC/NHSN criteria. A second limitation is
that this was an observational study in which treating physicians
were free to treat who they wanted and use whichever regimen
they deemed appropriate. Confounding by indication will occur in
this situation. As an example of this, we noted that receipt of
more than one active agent was associated with an increased
likelihood of failure. Another consequence is that the treatment
regimens were quite heterogeneous and difficult to analyse.
Interventional studies will be needed to determine the best
approach to CRKP UTI. A third limitation involves the difficulty
of assigning a definitive outcome to all patients. For about half
of the patients, the outcome was deemed indeterminate. To
address this issue, we performed not only ordinal analyses, but
also binomial analyses in both directions. In this way, we provided
a sensitivity analysis by grouping the patients either with an inde-
terminate outcome with patients who failed, or with patients
with a successful outcome. Furthermore, we repeated the mod-
els after exclusion of those patients who did not survive their
index hospitalization and found very similar results.
In summary, we found, in concordance with previously pub-
lished data, that aminoglycosides appear to be associated with
the best clinical outcomes in patients treated for CRKP bacteriuria.
This may inform the future design of the control arm in studies on
treatment of CRKP UTI with newer agents with activity against
carbapenem-resistant Enterobacteriaceae. In addition, we report
preliminary data linking the molecularly and clinically distinct
CRKP clade ST258A to worse clinical outcomes in CRKP bacteriuria.
This finding will need to be validated in other independent studies
to further our understanding of outcomes in K. pneumoniae
strains.
Table 4. Strain type analysis adjusted for treatment regimen
Pa aOR for successb Pb aOR for failurec Pc
ST258A versus other 0.0343 0.73 (0.12–3.74) 0.7120 5.82 (1.47–28.50) 0.0113
UTId 0.0575 4.32 (0.94–24.03) 0.0607 0.41 (0.10–1.50) 0.1807
Tigecycline 0.0094 0.15 (0.01–1.11) 0.0645 5.83 (1.46–28.52) 0.0116
Aminoglycoside 0.8147 0.54 (0.10–2.70) 0.4512 1.05 (0.29–4.05) 0.9413
The model includes the following variables: UTI, tigecycline, aminoglycoside and strain A versus all other.
aOrdinal logistic regression.
bBinomial logistic regression success versus all others.
cBinomial logistic regression failure versus all others.
dUTI as defined by CDC/NHSN.
Table 5. Strain type analysis adjusted for treatment regimen base
Pa aOR for successb Pb aOR for failurec Pc
ST258A versus other 0.0598 0.89 (0.14–4.62) 0.8935 5.07 (1.32–23.59) 0.0176
UTId 0.0169 5.23 (1.17–28.59) 0.0302 0.28 (0.06–1.05) 0.0587
Regimen base 0.1495 0.7233 0.1052
aminoglycoside (reference) — —
colistin 1.74 (0.19–13.35) 0.96 (0.16–5.31)
tigecycline 0.47 (0.02–4.18) 5.08 (1.07–29.31)
other 1.85 (0.20–14.14) 0.41 (0.04–2.84)
The model includes the following variables: presence of UTI, regimen base and strain A versus all other.
aOrdinal logistic regression.
bBinomial logistic regression success versus all others.
cBinomial logistic regression failure versus all others.
dUTI as defined by CDC/NHSN.
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